Burkholderia cepacia Complex Vaccines: Where Do We Go from here?
AbstractBurkholderia comprises a wide variety of environmental Gram-negative bacteria. Burkholderia cepacia complex (Bcc) includes several Burkholderia species that pose a health hazard as they are able to cause respiratory infections in patients with chronic granulomatous disease and cystic fibrosis. Due to the intrinsic resistance to a wide array of antibiotics and naturally occurring immune evasion strategies, treatment of Bcc infections often proves to be unsuccessful. To date, limited work related to vaccine development has been performed for Bcc pathogens. In this review, we have gathered key aspects of Bcc research that have been reported in recent years related to vaccine efforts, virulence, immune responses, and animal models, and use this information to inform the research community of areas of opportunity toward development of a viable Bcc vaccine. View Full-Text
Share & Cite This Article
Pradenas, G.A.; Ross, B.N.; Torres, A.G. Burkholderia cepacia Complex Vaccines: Where Do We Go from here? Vaccines 2016, 4, 10.
Pradenas GA, Ross BN, Torres AG. Burkholderia cepacia Complex Vaccines: Where Do We Go from here? Vaccines. 2016; 4(2):10.Chicago/Turabian Style
Pradenas, Gonzalo A.; Ross, Brittany N.; Torres, Alfredo G. 2016. "Burkholderia cepacia Complex Vaccines: Where Do We Go from here?" Vaccines 4, no. 2: 10.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.